Taysha Gene Therapies, Inc. (TSHA) NASDAQ

Currency In USD

Taysha Gene Therapies, Inc.

Address

3000 Pegasus Park Drive

Dallas, TX 75247

United States of America (the)

Phone

214 612 0000

Website

https://www.tayshagtx.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

September 24, 2020

Key Executives

Name	Title	Pay	Year Born
Sean Nolan	Chief Executive Officer & Chairman	1.19M	1968
Kamran Alam	Chief Financial Officer & Corporate Secretary	741,904	1978
Sukumar Nagendran	President, Head of Research & Development and Director	1.04M	1967
Berge Minassian	Chief Medical Advisor of UT Southwestern Gene Therapy Program	0	N/A
Hayleigh Collins	Director of Corporate Communications & Investor Relations	0	N/A
David McNinch	Chief Commercial Officer	0	1969
Frederick Porter	Chief of Staff & Technical Operations Officer	0	N/A
Sean McAuliffe	Chief Business Officer	0	N/A
Emily McGinnis	Chief Patient & External Affairs Officer	0	N/A
Rumana Haque-Ahmed	Chief Regulatory Officer	0	N/A
Steven Gray	Chief Scientific Advisor of UT Southwestern Gene Therapy Program	0	N/A

Description

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.